Related Experiment Video
Updated: Jul 15, 2026
04:40
Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
Deep vein thromboembolism in malignant diseases.
M Zemková1, R H B Meyboom, M Blazek
1Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden. Marcela.Zemkova@who-umc.org
Summary
Cancer patients often experience blood clots, a condition known as venous thromboembolism (VTE). Low-molecular-weight heparin (LMWH) is a more effective treatment for VTE in cancer patients than warfarin, with a similar bleeding risk.
Area of Science:
- Oncology
- Hematology
- Vascular Medicine
Background:
- Tumorous diseases are frequently linked to both hemorrhagic and thrombotic complications.
- A significant association exists between malignancy and venous thromboembolism (VTE), with 15-20% of VTE patients having an undetected malignancy.
- Migrating thrombophlebitis can be a specific indicator of underlying tumors, particularly pancreatic cancer.
Purpose of the Study:
- To review the pathogenesis of VTE in patients with cancerous diseases.
- To compare the efficacy and safety of long-term management strategies for VTE in cancer patients.
Main Methods:
- Review of existing literature on the association between tumors and VTE.
- Analysis of factors contributing to VTE pathogenesis in malignancy.
- Comparison of conventional therapy (Vitamin K antagonists - VKAs) with newer approaches (Low-Molecular-Weight Heparin - LMWH).
Main Results:
- Pathogenesis involves elevated coagulation, reduced fibrinolysis, immobilization, surgery, chemotherapy, hormonal therapy, and central venous catheters.
- Low-Molecular-Weight Heparin (LMWH) demonstrates higher efficacy in managing VTE in cancer patients compared to VKAs.
- LMWH offers this improved efficacy without a significantly increased risk of bleeding and eliminates the need for regular laboratory monitoring.
Conclusions:
- LMWH represents an effective and safe alternative to VKAs for long-term VTE management in patients with cancerous diseases.
- The evidence supports an updated, evidence-based approach to VTE treatment in this patient population.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:27Pulmonary Embolism III: Nursing Management
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...